Extensive cuts to NHS treatments could affect providers’ underwriting and lead to rising premiums, experts warn.
The Government announced earlier this month it will stop funding 25 cancer treatment drugs in a move designed to trim costs by up to £80m.
LV= head of underwriting Lisa Byrne says that while the removal of the cancer treatments itself would not affect pricing, an extensive campaign of further cuts to treatments currently provided by the NHS would soon be factored in to the price of protection.
She says: “We need to monitor longer-term trends and, if the Government continues to make cuts to the treatments available through the NHS, and it starts to impact on survival rates or mortality, that is a longer-term effect that will, of course, factor in to our pricing.
“If we saw those metrics starting to be affected by NHS cuts, or for that matter anything else, that would eventually be reflected in the way we price.”
Master Adviser partner Roy McLoughlin says: “In the worst-case scenario, premiums could rise, further distancing consumers, and that is the last thing you want to do.
“You could also see a situation where premiums remain the same but we get a lot more incidents of ratings, postponements or potentially claims being denied.
“Providers could get a lot more picky and the industry has had a tough enough time already.”